Merck Geschäftsbericht 2022 Berichtsarchiv Datenschutz Impressum Kontakt Sitemap Letzte Aktualisierung: 2. März 2023 © Merck KGaA, Darmstadt, Deutschland Verwendung von Cookies Wir verwenden Analysemethoden in Form von Cookies, um zu messen, wie häufig unsere Seite besuch...
The net income attributable to Merck KGaA shareholders increased by 8.9% to € 3,326 million (2021: € 3,055 million) and resulted in an improvement in earnings per share to € 7.65 in fiscal 2022 (2021: € 7.03).EBITDA pre, the key financial indicator used to steer oper...
Abbisko has built an extensive pipeline of 15 innovative small-molecule programs focused on precision oncology and immuno-oncology. “Pimicotinib is just the beginning,” Jiang said, noting that the company is in other deal discussions, and he expects numerous deals in 2024. Abbisko’s stock on...
Focused leadership approach to pipeline enrichment builds on expertise in key biology and therapeutic areas as well as technological capabilities Not intended for UK-based media DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germ...
The global strategic alliance with GlaxoSmithKline plc., United Kingdom, (GSK) for the joint development and marketing of the bintrafusp alfa (M7824) immunotherapy developed by Merck KGaA, Darmstadt, Germany, is one example of an opportunity for research and development in the Healthcare business...
28 Jun 2022 // FIERCEPHARMA Deeming success unlikely, Merck KGaA cuts lung cancer trial 04 Jun 2022 // FIERCEBIOTECH BMS, Merck KGa enter protein degradation race with $2.3B Amphista pact 05 May 2022 // BIOSPACE Aizon and aggity Launch Partnership to Help Biopharmaceutical Firms ...
splansto reunite its oncology unit with the rest of its pharma business and carve out a new C-suite post to oversee strategy and growth. The podcast team also previews how Merck KGaA (Xetra:MRK) ischangingthe way it is building its pipeline following late-stage clinical disappointments and ...
candidates through this collaboration; the obligations of the parties pursuant to the collaboration and license agreement; the therapeutic potential of Mersana’s product candidates, including those based on its Immunosynthen platform; the expected receipt of an up-front payment from Merck KGaA...
非在研机构 Merck KGaAFresenius Kabi SwissBioSim GmbH 最高研发阶段批准上市 首次获批日期 欧盟(2019-04-02), 强直性脊柱炎银屑病关节炎中轴性脊柱关节炎+ [10] 最高研发阶段(中国)- 特殊审评- 登录后查看时间轴 结构/序列 Sequence Code 26792L 当前序列信息引自: *** Sequence Code 88699H 当前序列信...
After two years and multiple trial failures, Merck KGaA, Darmstadt, Germany and GlaxoSmithKline have terminated a nearly $4 billion development agreement that centered on the experimental immunotherapy drug bintrafusp alfa. The termination of the deal was announced Thursday, mon...